Company profile
Voyageur Pharmaceuticals Ltd.
OTC: VYYRF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Calgary, ABReports USD
#1135 of 1,418 Healthcare companies by revenue
EA Score
——FH 28DQ —GM —SS 38
v0.1 · 35/100 weight · pillars only
↑ disclosure history, market scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$34.4k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.5M
Employees
6
as of 2026-08-21
Market cap
$21.5M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.3k11.7k CAD2025
Net income-$2.5M-3.5M CAD2025
Operating income-$2.5M-3.5M CAD2025
Total assets$2.2M3.1M CAD2025
Liabilities$1.3M1.9M CAD2025
Equity$894.9k1.3M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Voyageur Pharmaceuticals Ltd.’s revenue?
Voyageur Pharmaceuticals Ltd. booked $8.3k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -30232.7% net margin.
Peers · Healthcare
Baseline Productions, Inc.——SYBLEU Inc——Modern Mobility Aids, Inc.——Genelux Corporation32DBetter Therapeutics, Inc.——Kaya Holdings, Inc.——Key facts
CEOBrent Willis
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCalgary, AB
ExchangeOTC: VYYRF
Employees6
IPO date2017-10-19
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.